The 5-year survival is only about 30% when ovarian cancer (OC) is first detected at an advanced stage, which is the case for ~70% of women with OC. The combination of debulking surgery and cytotoxic chemotherapy is the primary treatment modality for OC. There has been much interest in the use of intraperitoneal (IP) chemotherapy for OC and the National Cancer Institute of the USA has endorsed this form of therapy. Disintegrins represent a class of disulfide-rich polypeptides, originally isolated from snake venom, many of which contain a cyclic-Arg-Gly-Asp (c-RGD) motif. Due to their ability to bind to integrins that are important to cancer progression and dissemination, disintegrins hold a significant translational potential as anti-cancer therapeutic agents. Integrins are heterodimeric adhesion receptors on the surface of cells that relay signals bi-directionally across the plasma membrane between the extracellular matrix and cytoskeletal proteins and signaling molecules inside the cell. They are closely associated with OC progression and dissemination. Multiple studies have demonstrated that adding IP therapy to intravenous therapy produces survival benefits in patients with advanced OC. We report the use of IP delivery of a recombinant disintegrin, vicrostatin (VCN), in mouse models of OC, which leads to highly effective inhibition of progression and dissemination of OC. When impregnated in a gel formulation VCN has extended time-release activity and retains therapeutic levels for 7-10 days; with weekly VCN injections activity is retained for prolonged times. This IP delivered formulation is effective against several human ovarian cancer cell lines, and warrants further translational studies.
Introduction
OC is a devastating disease with the serous histotype found in ~70% of cases and high-grade serous ovarian cancer (HGSOC) a most aggressive, highly-invasive subtype, which accounts for 90% of serous carcinomas and two-thirds of all OC deaths [1] . The standard treatment is aggressive surgery followed by adjuvant platinum-taxane chemotherapy. However, no efficient therapeutic method aimed at stopping OC dissemination is currently available in the clinic [2] . There has been much interest in the use of regional (intraperitoneal, IP) chemotherapy for OC and the National Cancer Institute of the United States has endorsed this treatment following publication of the results of three large randomized Phase III clinical trials [3] .
Disintegrins represent a class of disulfide-rich polypeptides, originally isolated from snake venom, which hold a significant translational potential as anti-cancer therapeutic agents. Disintegrins bind only to the activated conformation of integrins in motile cells such as cancer cells and angiogenic endothelial cells. Vicrostatin (VCN) is a monomeric disintegrin of ~7.1kDa that has been recombinantly expressed in E. coli. Its sequence is based on the natural snake venom disintegrin contortrostatin, a dimer found in the venom of the southern copperhead snake [4] . VCN has an Arg-Gly-Asp (RGD) motif at the tip of a flexible loop stabilized by disulfide bonds [4] . Interaction of VCN with multiple integrins (i.e., αvβ3, αvβ5, α5β1 and αIIbβ3), primarily through the RGD motif [4] , enables it to target both endothelial and OC cells. Potent antitumor activity of VCN has been previously described in models of both breast and prostate cancer [4, 5] . There were no visible side effects or signs of internal bleeding, indicating that in mice chronic administration of VCN is not cytotoxic [4] .
Integrins are heterodimeric adhesion receptors on the cell surface that relay signals bi-directionally across the plasma membrane between the extracellular matrix and signaling pathways and cytoskeletal proteins [6] . The  subunits combine with  subunits to create 24 unique   heterodimers resulting in a range of specificities toward extracellular matrix (ECM) proteins [6] . Several members of the integrin family recognize the RGD sequence present in ECM proteins [7] . Integrins (including αvβ3, αvβ5, α5β1) have important roles in OC cell attachment, survival, migration, invasion and angiogenesis [8] , and their involvement in processes critical to tumor progressio n suggests they would serve as attractive targets for cancer therapy [9] . The broad spectrum of integrin targets to which VCN binds make it an attractive therapeutic agent.
Materials and Methods

Materials
Vicrostatin (VCN) was recombinantly produced and HPLC purified according to an established protocol [4] . Oxiplex gel was obtained from FizioMed, San Luis Obispo, CA. OVCAR3 and SKOV3 cells were obtained from ATCC (Bethesda, MD). Both cell lines have been stably transfected by an adenovirus containing genes coding for luciferase (luc) and green fluorescent protein (GFP).
Cell Line and Culture
The established human ovarian cancer cell lines OVCAR3 and SKOV3 were used in these studies and were grown as monolayers in vitro. Cells were grown in RPMI 1640 (OVCAR-3), and McCoy's 5a modified medium (SKOV-3), at 37°C in a humidified incubator (5% CO2 and 95% air). Cells were harvested with trypsin-EDTA, washed with complete medium, and resuspended in PBS.
Spheroids are multicellular aggregates that can be grown in vitro from any human OC cell line by seeding cells in appropriate media and forcing the cells to grow in suspension by plating them on low binding surfaces. To generate spheroids from SKOV3
GFP/LUC cells, we coated multi-well plates with polyHEMA (poly{2-hydroxyethyl methacrylate}), and seeded cells in their regular medium and allowed them to form spheroids. Briefly, 1x10 6 cells were seeded per well (in 6-well plates) and allowed to aggregate for at least 48 hours. Then the spheroids were resuspended at a density of 20x10 6 cell equivalents/ml.
Animal Tumor Model
For the dispersed cell model both OVCAR3 and SKOV3 cells growing as a monolayer in culture were harvested and cells (2 x 10 7 ) were suspended in 1 ml PBS and 100 μl of the cell suspension was injected IP into five-week old female athymic nude mice (Balb/c/nu/nu). Each animal received 2 x 10 6 cells, dispersed cells or cell equivalents in the spheroid models, and the tumors were allowed to implant for 4-14 days before treatment was initiated; tumor growth was confirmed by bioluminescent imaging.
Release Kinetics of VCN from Oxiplex
We evaluated release kinetics for a number of different formulations of VCNimpregnated Oxiplex gel. We used identical volumes of Oxiplex (1ml) impregnated with 1, 3 or 10mg/ml VCN, and determined release kinetics.
Animal Imaging
To evaluate presence of tumor prior to initiating treatment and biweekly throughout the study, mice were imaged at the Molecular Imaging Center Core. Mice were injected intravenously with 50 mg/kg of D-luciferin in PBS 90 seconds prior to imaging. Imaging was performed using a charge-coupled device camera (IVIS 200, Xenogen-Caliper, Alameda, CA). Mice were anesthetized with isoflurane prior to and during imaging. Total photon flux (photons/sec) was measured from a fixed region-of-interest over the peritoneal space of the mice using Living Image software (Perkin Elmer, Waltham MA) [10] .
Results
Release Kinetics of VCN from Oxiplex
Oxiplex (1ml) impregnated with 1, 3 or 10mg/ml VCN was evaluated and it was determined that the release kinetics varied inversely with drug concentration (i.e., 10mg/ml being the slowest). For these studies, a very small volume of VCN (~50ul) was mixed with 1 ml of Oxiplex, ensuring that the gel was not diluted by more than 5%. VCN incorporated into Oxiplex at 2-10mg/ml resulted in a sustained release of the drug that lasted for 10-12 days (Figure 1 ). This sample was evaluated by measurement of released soluble 125I-VCN. VCN when impregnated in Oxiplex gel is released with an initial rapid rate of ~16% of the loaded material over the initial 2 days. The gel remains intact for>11 days releasing nearly 55% of the loaded VCN. Retention of VCN Efficacy Preliminary assess-ment of VCN-Oxiplex in a murine model of human OC was performed. OVCAR3 cells (2x10 6 ) were injected IP in nude mice and two weeks were allowed for tumors to develop before VCN-Oxiplex therapy was administered for four weeks. The animals received weekly either 1ml Oxiplex alone or 1ml Oxiplex impregnated with VCN (10mg/ml). At the end of the study the animals were dissected; the control group showed widespread tumor throughout the peritoneal cavity, while VCN-treated animals were devoid of macroscopic tumors on visual inspection.
Dose Response/Frequency Studies of VCN-Oxiplex
A dose-response study with VCN-Oxiplex using SKOV3 human OC cells was performed. These studies evaluated the effect on tumor dissemination of the administration of 1, 2.5 and 5mg VCN in 1ml Oxiplex delivered once per week, versus Oxiplex alone. Treated groups showed a significant decrease in the number of macroscopic foci as the VCN concentration increased; animals that received 5mg/ml of VCN-Oxiplex weekly showed no visible tumor.
To demonstrate the reliability of the bioluminescent signal from the luciferase expressing tumors, the SKOV3 GFP/LUC model was utilized and an inoculum of 2x10 6 cells was injected IP and tumors allowed to grow for 2 weeks prior to the initiation of therapy. Therapy consisted of 5 mg VCN delivered in 1 ml Oxiplex/week versus 1 ml Oxiplex alone/week for a 4-week course. VCN treated animals were essentially devoid of visible macroscopic tumor foci by gross examination, while Oxiplex alone animals showed extensive tumor dissemination throughout the peritoneal cavity. Bioluminescent imaging quantitation showed greater than 95% inhibition of tumor spread in the treated group after 4 weeks of treatment.
VCN-Oxiplex VS. VCN-Saline
In this study animals (10 animals per group) were inoculated with 0.1 ml of SKOV3 GEP/LUC spheroids (2x10 6 cell equivalent) IP and the spheroids were allowed to implant for 4 days. The animals received IP weekly 1 ml doses of either 5mg of VCN in saline, 5mg of VCN in Oxiplex, or Oxiplex alone. Animals in the Oxiplex alone group showed extensive carcinomatosis that was disseminated throughout the peritoneal cavity. Animals that received VCN-saline or VCN-Oxiplex showed dramatically less or no visible macroscopic tumor foci by gross examination (Fig. 2) . Quantitation of bioluminescent imaging reveals that VCN-Oxiplex and VCN-saline inhibit tumor growth by ~95-98% (Figure 3) . These results indicate that Oxiplex and saline delivery modalities are similarly effective. 
Discussion
Consistent findings in HGSOC include the activation of multiple components of the cellular invasion apparatus (i.e., invadosome-associated integrins and their downstream kinases) [11] . A more efficient and less toxic form of therapy aimed at addressing metastatic residual OC following surgery is urgently needed to prolong the survival and improve the quality of life of these patients. OC spheroids, unlike individual OC cells, are known to be much more resistant to chemotherapy. Unlike primary tumors and macrometastases, OC micrometastases evade detection at the time of surgery, and failure to eradicate them is the main reason for recurrence. We believe that an effective way of addressing this clinical problem is by the means of a broad-spectrum antiinvasive agent, and VCN represents such an anti-invasive therapeutic.
What complicates the management of OC is that chemotherapy administered intravenously (IV) penetrates only poorly into the peritoneal compartment where the disease is actually spreading. One solution to this problem is the administration of chemotherapy directly to the intraperitoneal space after debulking surgery, and in advanced OC a 21.6% decrease in the risk of death was reported in patients undergoing combined IP and IV therapy versus those undergoing IV therapy alone [12] . Although efficacious, the regimens of currently used IP platinum and taxane agents are accompanied by dramatic off-target toxic effects. This is the main reason why a significant number of women opt out of the IP treatment despite its potential benefits.
We propose a radically new approach aimed at delaying the further dissemination of OC in the post-debulking surgery setting, and we have developed a non-toxic engineered disintegrin, a peptide called vicrostatin (VCN) with broad-spectrum anti-integrin activity (i.e., against multiple  v and 5 integrin members that are uniformly upregulated in OC). VCN acts thro ugh a mechanism that involves high-specificity binding to invadosome-associated tumoral integrins displayed by OC cells [13] . This anti-invasive mechanism is experimentally supported by encouraging preliminary studies with xenograft models of OC, as described here. At the molecular level VCN demonstrates its anti-invasive activity by disrupting the actin cytoskeleton organization as we previously showed [4] . To our knowledge, a therapeutic solution like this, involving delivery of a targeted, anti-invasive drug directly in the IP space in OC patients immediately after debulking surgery has never been tested in clinic.
